ON-DEMAND WEBINAR
Duration: 1 hour

​
Passive safety surveillance for post-marketed drugs is frequently undermined by incomplete, inconsistent and insufficient data. Safety scientists, epidemiologists and other researchers are increasingly integrating population-based real-world data (RWD) into all phases of their safety assessments to enhance the reliability of their data.

In our latest webinar, we'll discuss:

• The increasing use of RWD by regulators and the relative importance attached to it in their activities
• The way regulators and pharmaceutical companies are increasingly relying on RWD to tackle difficult points of signal management, including those where other types of data are not useful
• A balanced demonstration of the operational details, usefulness and limitations of a method recommended to refine signals using RWD that overcomes many of the limitations inherent to other types of data

SPEAKERS  

Ruben Ayzin Rosoky, MD, PhD, MFPM
Senior Safety Physician,
Expert in complex signal assessment

Irene Cosmatos, MS
Senior Research Specialist,
Expert in using RWD for postmarketing safety surveillance